Navigation Links
AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
Date:10/16/2007

NEW YORK, Oct. 16 /PRNewswire-FirstCall/ -- AngioGenex Inc. (OTC Bulletin Board: AGGX.OB) has identified and filed a patent application on small molecules that are potent inhibitors of the Id proteins. "The identification of these lead molecules and the filing of this patent constitute major milestones in the Company's goal to develop orally active anti-cancer drugs," said Dr. Richard Salvador, President and CEO, and the former global head of Preclinical Development at Hoffmann La Roche, Inc. He further stated that, "the work embodied in this patent establishes the 'drugability' of the Id proteins as targets allowing the Company to move forward with the preclinical work required to bring these molecules into the clinic."

According to Dr. William Garland, VP & Head of R&D, "both the in vitro and in vivo studies indicate that our small molecule inhibitors of the Id proteins will block angiogenesis and malignant transformation of cells responsible for tumor growth in man, and are likely to be orally active." Further, "inhibition of the Id proteins by these small molecules is unlikely to cause serious adverse effects in patients since they are not known to be required for the normal function of cells of the body. Their only function, with minor exceptions, is to promote blood vessel formation into tumors."

AngioGenex is currently testing a companion diagnostic that detects low levels of the Id proteins in serum. This diagnostic was developed in collaboration with BioCheck, Inc. of Foster City, California. Preliminary clinical results suggest that it has the potential to detect the presence of Id proteins at an early stage of tumor development allowing early medical intervention; it may also be useful to either follow the course of therapy or to determine whether there is a recurrence of disease.

AngioGenex, Inc. is actively engaged in the discovery, acquisition and development of anti-cancer molecules that act by inhibiting either the Id genes o
'/>"/>

SOURCE AngioGenex Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
2. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
3. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
4. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
5. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
6. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
7. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
8. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
9. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
10. First Demonstration of nanoImmunology: a Nanomaterials-based Therapeutic Approach to Treat Allergy
11. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)...  Genomic Health, Inc. (Nasdaq: GHDX ) ... from a health economic analysis suggesting that use of ... a significant reduction in direct medical costs and improve ... effects of unnecessary treatment.  "By providing ... measures, as demonstrated in this analysis, the Oncotype DX ...
(Date:9/12/2014)... 12, 2014 Sepsis is a life ... worldwide.  Education and awareness are fundamental to improving ... marks Sepsis Awareness Month and September 13 th ... Sepsis Alliance, "Sepsis, the body,s toxic reaction to ... every year, and thousands more are left with ...
(Date:9/11/2014)... DUBLIN, Ireland , September 11, ... ,Research and Markets ( http://www.researchandmarkets.com/research/lqkmlx/radio_frequency ) has ... Radio Frequency Identification (RFID) Market in ... Cabinets) - Industry Analysis, Size, Share, ...  report to their offering.  ,     (Logo: ...
Breaking Medicine Technology:Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 2Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 3Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 4Genomic Health Announces Publication of Colon Cancer Cost-Effectiveness Study in PharmacoEconomics 5Nanomix Supports Sepsis Awareness 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 3
... 2012 Reportlinker.com announces that a new ... catalogue: Top 200 Biopharmaceuticals ... http://www.reportlinker.com/p0572074/Top-200-Biopharmaceuticals-Industry-Report-Global.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharma The Global Biopharmaceuticals ... This report is an in-depth ...
...  Questcor Pharmaceuticals, Inc. (NASDAQ:   QCOR) today announced ... preparing to issue a report regarding the Company,s ... statement: The Company believes that its ... requirements and industry standard practices.  Questcor markets H.P. ...
Cached Medicine Technology:Top 200 Biopharmaceuticals Industry Report (Global) 2Top 200 Biopharmaceuticals Industry Report (Global) 3Top 200 Biopharmaceuticals Industry Report (Global) 4Questcor Pharmaceuticals Issues Statement 2
(Date:9/13/2014)... Va. (PRWEB) September 13, 2014 Happiness is ... to healthier living and achieving goals. That's what LWell ... pleased to announce that Stephens, a life coach who has ... was a teenager, will present her "Happiness is a Choice" ... 6:30 p.m. , This event is being offered ...
(Date:9/13/2014)... MD (PRWEB) September 13, 2014 Deaf Awareness ... The Hearing and Speech Agency hosts a week-long ... Sign Language (ASL) as the main form of communication. ... the schedule includes an ASL film night, a yoga class, ... open to the entire community. , The schedule is as ...
(Date:9/13/2014)... (PRWEB) September 13, 2014 Motion Graphics artist ... new transition pack entitled TransPack Volume 2 exclusively for Final ... fun way to transition from one clip to the next.” ... can never have too many transition options and TransPack Volume ... TransPack Volume 2 is a package of 30 thematic transitions ...
(Date:9/13/2014)... September 13, 2014 Although it’s cooled ... into mosquito high season are the state’s southern cities ... areas. With a rise in mosquitoes carrying West ... a partnership with Dixie State University’s Dr. Barnum and ... a product called NutriVex. , NutriVex is in its ...
(Date:9/12/2014)... As low testosterone lawsuit claims continue ... two of the U.S. Food & Drug Administration (FDA) ... to discuss controversial public health issues surrounding testosterone replacement ... and the Drug Safety and Risk Management Advisory Committee ... population for testosterone replacement therapy and the potential risk ...
Breaking Medicine News(10 mins):Health News:“Happiness is a Choice” Life Coaching Seminar Open to Community 2Health News:“Happiness is a Choice” Life Coaching Seminar Open to Community 3Health News:Baltimore Nonprofit Celebrates Deaf Awareness Week 2Health News:Baltimore Nonprofit Celebrates Deaf Awareness Week 3Health News:Today a new TransPack Volume 2 transition was announced from Pixel Film Studios for Final Cut Pro X. 2Health News:Dixie State University Partners with Utah Marketing Firm and the SW Mosquito Abatement and Control District for Product Testing 2Health News:Dixie State University Partners with Utah Marketing Firm and the SW Mosquito Abatement and Control District for Product Testing 3Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 2Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 3Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 4Health News:Testosterone Lawsuit Claims Continue As FDA Holds Meeting On Health Risks Associated "Low-T" Drugs Such As AndroGel 5
... Organisation (WHO) Monday hailed the progress of governments of Western ... region needed greater effort to effectively control the disease. ... of detecting at least 70 percent of TB cases and ... Maaren, regional adviser for the health body's TB programme. ...
... miniature robot that can be inserted through an incision ... body. ,Researchers from Ritsumeikan University and the ... that is controlled remotely once placed inside the body. ... centimeters (0.79 inches) in length and one in diameter. ...
... that some patients who complete bariatric surgery can develop ... deficiency, called Wernicke encephalopathy. , The researchers ... about their conclusions by extensive survey of data relating ... surgery. , The syndrome - Wernicke encephalopathy ...
... inhaled anesthetics increase the number of amyloid plaques in ... of neurodegenerative diseases like Alzheimer's. ,Roderic Eckenhoff, ... Pennsylvania's Department of Anesthesia and Critical Care, and his ... edition of Neurobiology of Aging. ,Every year ...
... hardly 29 per cent of the asthmatic children surveyed had ... as a dangerous trend for not vaccinating their kids against ... officials have warned. ,Actually it has been warned ... fall victims to pneumonia or acute respiratory disease. Inactivated flu ...
... possibly hazardous chemicals called polybrominated diphenyl ethers (PBDEs). The ... and Technology and the Environmental Protection Agency of the ... clear how dangerous these PBDEs are, though some types ... is strikingly similar to that of PCBs, which are ...
Cached Medicine News:Health News:WHO Calls for Greater Efforts to Fight TB 2Health News:Inhaled Anesthetics Accelerate the Onset of Neurodegenerative Diseases Like Alzheimer's 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: